Przeszczepienie allogenicznych krwiotwórczych komórek macierzystych w leczeniu chorych na mielofibrozę

@inproceedings{Patkowska2017PrzeszczepienieAK,
  title={Przeszczepienie allogenicznych krwiotw{\'o}rczych kom{\'o}rek macierzystych w leczeniu chorych na mielofibrozę},
  author={Elżbieta Patkowska and Joanna G{\'o}ra-Tybor},
  year={2017}
}
Within Ph-negative myeloproliferative types of cancer, myelofibrosis is the most frequent indication for performing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Because this is a high-risk procedure, only those patients with a predicted overall survival below 5 years become eligible, as well as those of intermediate-2 or high disease risk; as defined by the IPSS, DIPSS and DIPSS Plus prognostic indices. It has however recently been recognised that patients with a poor… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 70 REFERENCES

Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research.

  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2014
VIEW 15 EXCERPTS
HIGHLY INFLUENTIAL

Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) predict transplantation outcomes? A prospective multicenter validation study of the Kanto Study Group for Cell Therapy.

  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2012
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Allogeneic Stem Cell Transplantation in Myelofibrosis.

  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2017
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…